Vaxart to Present Research on Second-Generation Norovirus Oral Pill Vaccine Candidate at IDWeek 2025
Vaxart (OTCQX: VXRT) will present research on its second-generation norovirus oral pill vaccine candidate at IDWeek 2025 in Atlanta, held October 19–22, 2025.
The presentation, titled “An Open-Label Phase 1 Clinical Trial Demonstrating Improved Immune Responses to Norovirus Strains GI.1 and GII.4 from a Next Generation Oral Bivalent Vaccine Candidate”, is scheduled for Monday, October 20, 2025, 1:45 PM–3:00 PM ET in room B401-B402 and will be delivered by Nicholas J. Bennett, MBBChir, PhD.
Vaxart (OTCQX: VXRT) presenterà ricerche sul suo candidato vaccino orale contro il norovirus di seconda generazione, presso IDWeek 2025 a Atlanta, che si terrà dal 19 al 22 ottobre 2025.
La presentazione, intitolata "Uno studio clinico di fase 1 in aperto che dimostra risposte immunitarie migliorate ai ceppi del norovirus GI.1 e GII.4 da un candidato vaccino orale bilanciato di prossima generazione", è prevista per lunedì 20 ottobre 2025, ore 13:45–15:00 ET nella sala B401-B402 e sarà presentata da Nicholas J. Bennett, MBBChir, PhD.
Vaxart (OTCQX: VXRT) presentará investigación sobre su candidato a vacuna oral contra el norovirus de segunda generación, en IDWeek 2025 en Atlanta, que se celebrará del 19 al 22 de octubre de 2025.
La presentación, titulada “Un ensayo clínico de fase 1, abierto, que demuestra respuestas inmunitarias mejoradas a las cepas GI.1 y GII.4 del norovirus a partir de un candidato vacunológico oral bivalente de próxima generación”, está programada para lunes 20 de octubre de 2025, de 1:45 p.m. a 3:00 p.m. ET en la sala B401-B402 y será impartida por Nicholas J. Bennett, MBBChir, PhD.
Vaxart (OTCQX: VXRT)는 2세대 노로바이러스 경구 알약 백신 후보에 대한 연구를 IDWeek 2025에서 애틀랜타에서 발표하며, 행사는 2025년 10월 19일부터 22일까지 개최됩니다.
발표 제목은 “다음 세대 구강 이중가백 백신 후보로부터 GI.1 및 GII.4 노로바이러스 균주에 대한 면역 반응이 향상되었음을 보여주는 오픈 라벨 1상 임상시험”이며, 2025년 10월 20일 월요일 오후 1:45–3:00 ET에 B401-B402호에서 열리며 Nicholas J. Bennett, MBBChir, PhD가 발표합니다.
Vaxart (OTCQX: VXRT) présentera des recherches sur son candidat vaccin oral contre le norovirus de seconde génération lors de IDWeek 2025 à Atlanta, qui se déroulera du 19 au 22 octobre 2025.
La présentation, intitulée « Un essai clinique de phase 1 en ouverture démontrant des réponses immunitaires améliorées aux souches GI.1 et GII.4 du norovirus à partir d'un candidat vaccin oral bivalent de prochaine génération », est prévue pour lundi 20 octobre 2025, de 13h45 à 15h00 ET dans la salle B401-B402 et sera présentée par Nicholas J. Bennett, MBBChir, PhD.
Vaxart (OTCQX: VXRT) wird Forschung zu seinem Zweitgeneration-Noro-Virus-Oral-Pill-Vakzin-Kandidaten präsentieren, auf IDWeek 2025 in Atlanta, das vom 19. bis 22. Oktober 2025 stattfindet.
Die Präsentation mit dem Titel „Ein Open-Label-Phase-1-Klinischer Versuch, der verbesserte Immunantworten gegen Noro-Virus-Stämme GI.1 und GII.4 von einem nächsten Generation Oral Bivalent Vaccine Candidate zeigt“ ist geplant für Montag, 20. Oktober 2025, 13:45–15:00 Uhr ET im Raum B401-B402 und wird von Nicholas J. Bennett, MBBChir, PhD vorgetragen.
Vaxart (OTCQX: VXRT) ستقدم بحثاً حول مرشح اللقاح الفموي من الجيل الثاني لفيروس النوروفيروس في IDWeek 2025 في أتلانتا، من 19 إلى 22 أكتوبر 2025.
العرض، بعنوان « تجربة عشوائية مفتوحة من المرحلة 1 تُظهر استجابات مناعية محسّنة لسلالات النوروفيروس GI.1 و GII.4 من مرشح لقاح فموي ثنائي التوليف من الجيل التالي »، مدمج في الإثنين 20 أكتوبر 2025، من 1:45 م إلى 3:00 م بتوقيت شرق الولايات المتحدة في القاعة B401-B402 وسيقدمه Nicholas J. Bennett, MBBChir, PhD.
Vaxart (OTCQX: VXRT) 将在 IDWeek 2025 于亚特兰大展示其二代诺如病毒口服片剂疫苗候选者的研究，该会议将于 2025 年 10 月 19–22 日举行。
此次演讲题为 “一个开放标签的 Phase 1 临床试验，显示来自下一代口服双价疫苗候选者的 GI.1 与 GII.4 诺如病毒株的免疫应答改善”，计划于 2025 年 10 月 20 日，星期一，东部时间 1:45 PM–3:00 PM 在 B401-B402 会议室，由 Nicholas J. Bennett, MBBChir, PhD 主讲。
- None.
- None.
SOUTH SAN FRANCISCO, Calif., Oct. 20, 2025 (GLOBE NEWSWIRE) -- Vaxart, Inc. (OTCQX: VXRT) (“Vaxart”), a clinical-stage biotechnology company developing a range of oral recombinant pill vaccines based on its proprietary delivery platform, today announced that it will present research featuring its second-generation norovirus oral pill vaccine candidate at IDWeek 2025 taking place October 19-22, 2025, at the Georgia World Congress Center in Atlanta.
IDWeek Oral Abstract Presentation:
Presentation Title: An Open-Label Phase 1 Clinical Trial Demonstrating Improved Immune Responses to Norovirus Strains GI.1 and GII.4 from a Next Generation Oral Bivalent Vaccine Candidate
Session Title: Late Breaking Trial Results For Viral and Bacterial Infections
Presenter: Nicholas J. Bennett MBBChir, PhD, Vaxart Medical Director
Session Date and Time: Monday, October 20, 2025, 1:45 PM - 3:00 PM ET
Location: B401-B402
About Vaxart
Vaxart is a clinical-stage biotechnology company developing a range of oral recombinant vaccines based on its proprietary delivery platform. Vaxart vaccines are designed to be administered using pills that can be stored and shipped without refrigeration and eliminate the risk of needle-stick injury. Vaxart believes that its proprietary pill vaccine delivery platform is suitable to deliver recombinant vaccines, positioning the company to develop oral versions of currently marketed vaccines and to design recombinant vaccines for new indications. Vaxart’s development programs currently include pill vaccines designed to protect against coronavirus, norovirus and influenza, as well as a therapeutic vaccine for human papillomavirus (HPV), Vaxart’s first immune-oncology indication. Vaxart has filed broad domestic and international patent applications covering its proprietary technology and creations for oral vaccination using adenovirus and TLR3 agonists.
Contact
Vaxart Media and Investor Relations
Matt Steinberg
FINN Partners
IR@vaxart.com
(646) 871-8481
This press release was published by a CLEAR® Verified individual.
FAQ
What will Vaxart (VXRT) present about its norovirus vaccine at IDWeek 2025?
When and where is Vaxart's VXRT presentation at IDWeek 2025?
Who is presenting Vaxart's VXRT norovirus data at IDWeek 2025?
What is the title of Vaxart's VXRT IDWeek 2025 abstract?
Which norovirus strains are covered by Vaxart's VXRT vaccine candidate presented at IDWeek 2025?
Is Vaxart's VXRT norovirus presentation at IDWeek 2025 categorized under late-breaking results?
